|
| GOLD SPONSORS |
|
|
|
|
|
| SILVER SPONSORS |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| OCTOBER 26, 2011, THE METROPOLITAN CLUB, NYC |
|
|
Emerging Manager Showcase E
|
|
|
 |
Steve Edwards
Principal and Portfolio Manager
Frontera Management
|
| Steve Edwards is Principal and Portfolio Manager at Frontera Management in Norwalk, Conn., which was founded in 2009 and runs a systematic, yet fundamentally-driven macro strategy. Frontera has more than $42 million in assets under management. From 2004 to 2008, Mr. Edwards was Portfolio Manager and Research Analyst at the $3.5 billion investment management firm Spruce Private Investors, where he researched and designed the firm’s fundamentally-based systematic macro investment process and managed clients’ portfolios and a derivative-based, global macro overlay within the firm’s multi-manager hedge fund of fund products. Prior to that, he was at Bridgewater Associates from 2002-2003, where he served in the quantitative research and client analytics groups in support of the diversified, absolute-return global macro strategy and developed a trading system for global equities, nominal bonds, short rates, and currencies. He holds an A.B. degree in history from Princeton University in 2001, earning magna cum laude and Phi Beta Kappa honors, and became a CFA charterholder in 2006. |
|
|
|
|
Peter Keenan
Director of Managed Investments
Kottke Associates
|
| Peter Keenan is Director of Managed Investments at Kottke Associates, a Commodity Trading Advisor (CTA), proprietary trading firm and futures brokerage based in Chicago and founded in 1988. In the last 16 years Kottke Associates has managed close to $1 billion with the largest single program having close to $400 million in assets under management. The new Kottke Metal-Alpha Trading Strategy is a multi-strategy discretionary metals trading fund.
Mr. Keenan managed a group of electronic traders at Kottke from 2007 until January, 2011, when he was named to his current position. Prior to that, he worked as a senior trader with Geneva Trading. Previously, he worked for Cargill’s Grain Division as a Corn Options Specialist on the floor of the CBOT. He had a prior stint with Kottke before joining Cargill, serving as Managing Director of Kottke’s London office, where he managed a group specializing in interest rate products. In his role, Keenan oversaw all trading by the group on the London International Financial Futures Exchange (LIFFE) where he was a seat holder, as well as a member of the Euro-Swiss Pit Committee. Keenan has been member of the CBOT, the CME and the LIFFE Exchange, and has served as a member of various pit committees. |
|
|
|
|
Mark Pearl
Co-Founder
TruColor Capital Management
|
| Mark Pearl co-founded New York-based TruColor Capital in December, 2011, to pursue a long bias emerging market strategy with embedded capital protection. Together with Co-Founder Arlen Rockefeller, the former Global Equity Chief Investment Officer of State Street Global Advisors, they have been trading proprietary money since the launch and are now seeking outside investors.
Prior to TruColor, Mr. Pearl was the Managing Partner at Henderson Capital Management, a captive fund-of-hedge funds. Before that, he was a partner at Psilos, a health care-focused venture capital firm in New York. Prior to Psilos, Mr. Pearl worked with the founders of FedEx to create Medical Logistics, a national healthcare-specific courier company that raised over $100M in private equity. Previously, he was a founder of healthcare Internet company Care Agents, which was sold to CareInsite and is now known as WebMD. Mr. Pearl served as a member of the Greenwich Roundtable committee, which published the white paper Best Practices in Hedge Fund Investing: Due Diligence for Equity Strategies, in spring 2005. He also edited and co-authored an article entitled Best Practices for Hedge Funds, published in the Journal of Alternative Investments. He also served in Citigroup’s healthcare investment banking group. Mr. Pearl received his M.B.A. from Harvard Business School with second year honors and his M.B.B.S. (equivalent of M.D.) from the University of Melbourne, Australia. |
|
|
|
|
Lindsay A. Rosenwald
Co-Founder
Opus Point Partners
|
| Dr. Lindsay A. Rosenwald is Co-Founder of Opus Point Partners with Michael Weiss. Opus invests across healthcare, with a focus on biotechnology and life sciences, making open-market purchases as well as direct investments in publicly-traded companies, primarily through its Innovations Fund, launched August, 2008 and its Low Net Fund, launched January, 2009. The firm is located in New York City and currently manages about $70 million in assets. Prior to Opus Point, Dr. Rosenwald was the founder and Chairman of the Paramount Group of Companies, which were focused on the development of promising drugs. One of Dr. Rosenwald’s most recent accomplishments was the sale of his company, Cougar Biotechnology, a firm with a specific focus on prostate cancer, to Johnson & Johnson for about one billion dollars after results from Phase II clinical trials were available. From 1994 to 2007 Dr. Rosenwald was the investment manager of the Aries Funds, long/short alternative investment funds. From 2002 through 2006 he managed the Orion Fund, which was a committed capital fund dedicated to private investments in biotechnology, in particular PIPEs. Dr. Rosenwald received his M.D. from Temple University School of Medicine in 1983 and his B.S. in Finance from Pennsylvania State University in 1977. He maintained a private practice for two years, and in 1986 he moved to Wall Street to develop his career as a physician/analyst. |
|
|
|
|
